I also need to declare that I have had a pleasure to collaborate with profs. Buchbinder and Harris, albeit on the completely different topic (sham surgery controlled trials). I leave it to the editors to judge how much this may have influenced my judgment of their work now.
REVIEW RETURNED
25-Feb-2017
GENERAL COMMENTS
Thank you for this opportunity to review the manuscript referred above, submitted to the BMJ Open. This is a very well written trial protocol from a group that has contributed a number of pivotal studies to our discipline.
General comments This is a solid protocol on a topic of utmost clinical interest, as the distal radius fractures (DRF) are the most common fracture type in the elderly and despite quite a convincing body of evidence indicating no benefit from surgery (over conservative treatment), surgery still dominates as the treatment of choice of these injuries in many countries.
The authors have identified an evidence 'void' in need of addressing and have written a trial protocol according to the current standards (SPIRIT), a paper that properly "frames" the study question (existing evidence and the justification for this trial) and which then provides in a sufficient detail the methodology to be used. So, overall there are no major flaws/requests for edits, rather some remarks to be considered:
1. The inclusion of an observation cohort of those unwilling to be randomized but consenting to the follow-up, is an obvious strength of the plan, particularly given their somewhat "murky" estimate of only a 1/3 success rate in enrollment (basing on their experience from a recently completed, similar multicentre fracture trial). Such a major potential selection bias needs to be addressed and the authors seem to have found a way to do it properly. This "RCT within a cohort"-design hopefully becomes a standard of practice in (surgical) RCTs.
2. Inclusion criterion #2/Thresholds for displacement & angulation (fracture alignment). It appears to me that the authors have decided to determine this criterion prior to reduction while some of the previous studies have first performed closed reduction and casting before either: a) determining fracture alignment, b) classifying fractures into stable or unstable (after closed reduction), c) following up on patients after closed reduction to determine whether the fracture proves to be stable/unstable. Obviously, we have different treatment strategies/algorithms around the world despite seemingly similar healthcare systems and I am not arguing that one would be better than the other, rather just trying to clarify the potential effect of this methodological choice on the study population.
If I have understood this methodological choice correctly (there seems to be an obvious difference between the CROSSFIRE and (some of) the previous trials?), then a few words on the rationale and potential ramifications of the decision seem warranted: Are you going to enroll (roughly) the same population or possibly patients with "less/more severe" fractures than the previous trials?
3. Adverse events / fracture non-union: The authors list "fracture non-union" as an adverse event, but I found no mention whether they plan to routinely x-ray patients at 6 months (or at a later time point) or whether the need of x-ray is determined by symptoms? If the latter, then one could consider adding "symptomatic fracture non-union" (although asymptomatic non-union has little clinical relevance in the end..)?
4. Cast group: The authors note: "Participants in this group will be treated with a closed reduction and cast immobilisation, avoiding wrist flexion, within 2 weeks of the initial injury."
-Avoiding wrist flexion: Although I fully agree with the authors" decision to aim for a more "neutral position" of the wrist in the cast group, I wonder whether a brief rationale for this would be warranted? In the end, the classic "pronation-flexion-ulnar deviation"-combo was the treatment-of-choice for decades and some might still argue for its merits…?
-"…within 2 weeks of the initial injury": Just to be absolutely sure I understand the authors" intentions correctly, you plan to consider someone with a 14 day old wrist fracture (with no prior treatment) to be eligible for randomization? I do realize that there is really no point in setting too stringent of a threshold for this, but I wonder whether the "anticipatable treatment efficacy" of both interventions are equal at this "somewhat late" time point? For the surgery group, this should not make a difference, as the fracture can still be "quite easily" reduced (after some excision of the preliminary callus/scarring at the fracture site), but does the same apply to closed reduction (cast group)? One could obviously say that this is essentially what you plan to study, but my concern is that even so, the "anticipatable prognosis" is not necessarily the same. Having said all this, I do realize that my concern is truly valid for those > 10 days post-injury, who most likely represent a minority of the patient population. Nevetheless, a comment (even in the response letter) seems appropriate.
REVIEWER
Jonas Bloch Thorlund University of Southern Denmark, Denmark REVIEW RETURNED 01-Mar-2017
GENERAL COMMENTS
Thank you for the opportunity to review this interesting and very well written protocol paper. It is unclear to this reviewer if the study has already commenced. Thus, all comments are given as has the study not started yet. If recruitment has started please disregard comments that cannot be changed at this time. My most important comments relate to the collection of adverse events, the suggested analysis of data and the implication of the large amount of study sites. Other than that, comments are very minor.
Introduction:
The introduction is very well written and argues well for the presence of equipoise justifying this study.
Page 7, lines 11-12: The word "of" is missing between "most these".
Page 7, line 30: Suggest to remove the word "of" after "In 2011, of…"
Method and Analysis: Page 9, lines 24-25: Suggest labeling the primary outcome as " patient reported outcome" rather than "questionnaire" as this may cover all sorts of things. Also, I would suggest, if possible, to collect all information electronically to facilitate less loss of data in paper format, given the large amount of study sites.
Page 10, lines 44-47: It is not clear for this reviewer what stratification for "minimisation" cover. What do the authors mean by adjusting the randomization for gender and age? Does this also cover stratification? Adjusting is a term that is usually reserved for the statistical analysis in order to try to take confounding factors into account.
Page 10-11: I would suggest the authors to stick to the "plate group" and "cast group" labeling and refrain from "intervention" and "control". The authors very nicely outlined that there is almost a 50/50 split in the use of treatments thus I believe simply labeling the groups for what they are would be more correct.
Page 11, lines 45-49: I would suggest providing the home exercise program in a supplementary appendix. The exercise part of trials is usually poorly described not allowing for full replication in clinical practice afterwards.
Page 12, secondary outcomes: I would strongly suggest the authors NOT to try and make a predefined exhaustive list of adverse events (complications). Recording of adverse events is a challenge.
Preferably ALL adverse events should be recorded disregarding any causal relationship with the treatment/injury. Adverse events tend to be underestimated if such causal relation is trying to be inferred and these are most often based on nothing more than personal opinion. In addition, some form of adjudication panel is usually recommended.
Page 12, sample size: Have the authors considered that with 32 sites, each site will on average only include 5 patients for the trial (and around 15 patients in total including the cohort). Could this have any impact on the data? Often (though similar) some practice variation in the delivery of treatment exists between sites -have the authors considered to deal with this in any way?
Page 13, data analysis: I have some concerns regarding the statistical analysis. First of all, I do not understand why the primary outcome/analysis is the PRWE score at 12 months. As I understand this score is also collected at baseline (I am not particular familiar with this score). Usually, when trying to assess if one treatment provide better improvement than the other the primary outcome is the between group difference in change from baseline to the primary follow-up point (in this case 12 month). Testing the difference at 12 month does, strictly speaking, not answer the study question in this reviewers opinion. In addition, I would suggest using some form of repeated measures analysis for the primary analysis (i.e. mixed linear random effects model or similar). This type of model will take into account loss to follow-up and use all available data improving point estimates and narrowing confidence intervals. With the present analysis approach (i.e. t-test) only patients with data at 12 months will be used in the analysis.
It is also unclear how missing data will be treated. The authors write that this will be done in accordance with the different outcome tools. However, I guess this only provide a solution for missing ITEMS on the individual outcomes scores? What will the authors do with those patients who are missing completely at one or more follow-ups (lost to follow-up) at the primary end point? I think that the "no missing data imputation" will be a poor option (i.e. implying only those with full data set will be analyzed -this is generally not what intention to treat analysis cover).
VERSION 1 -AUTHOR RESPONSE
Reviewer: 1 General comments This is a solid protocol on a topic of utmost clinical interest, as the distal radius fractures (DRF) are the most common fracture type in the elderly and despite quite a convincing body of evidence indicating no benefit from surgery (over conservative treatment), surgery still dominates as the treatment of choice of these injuries in many countries. Thank you, no response required
Specific comments 1. The inclusion of an observation cohort of those unwilling to be randomized but consenting to the follow-up, is an obvious strength of the plan, particularly given their somewhat "murky" estimate of only a 1/3 success rate in enrolment (basing on their experience from a recently completed, similar multicentre fracture trial). Such a major potential selection bias needs to be addressed and the authors seem to have found a way to do it properly. This "RCT within a cohort"-design hopefully becomes a standard of practice in (surgical) RCTs. Thank you, no response required 2. Inclusion criterion #2/Thresholds for displacement & angulation (fracture alignment). It appears to me that the authors have decided to determine this criterion prior to reduction while some of the previous studies have first performed closed reduction and casting before either: a) determining fracture alignment, b) classifying fractures into stable or unstable (after closed reduction), c) following up on patients after closed reduction to determine whether the fracture proves to be stable/unstable. Obviously, we have different treatment strategies/algorithms around the world despite seemingly similar healthcare systems and I am not arguing that one would be better than the other, rather just trying to clarify the potential effect of this methodological choice on the study population. This inclusion criteria are consistent with the treatment algorithm as practised in Australia. All investigators have been consulted and have agreed to the inclusion criteria as they are described. See also next response for further explanation.
If I have understood this methodological choice correctly (there seems to be an obvious difference between the CROSSFIRE and (some of) the previous trials?), then a few words on the rationale and potential ramifications of the decision seem warranted: Are you going to enrol (roughly) the same population or possibly patients with "less/more severe" fractures than the previous trials? The study inclusion criteria will differ from Arora et al (2011) as it will include all patients presenting with displaced fractures, regardless of the results of an initial closed reduction. In some countries, "stability" is decided on repeat radiographs after one week, and then a decision made on closed versus open treatment. This is the method used in the previous Arora (2011) trial. In many other countries, including Australia, the treatment decision (and assessment of stability) is made on the initial radiographs (degree of displacement) with no trial of closed treatment first. CROSSFIRE reflects that practice by randomising based on the initial films. It is the consideration of many surgeons (particularly in Australia and the US) that "stability" is decided on the initial films (displacement, comminution) and "reducibility" decided on the post-reduction films. This has been clarified in the manuscript as follows: "Furthermore, this study only included patients in whom the initial closed reduction had failed on first review, a practice not followed in Australia, where the decision to operate is made on initial presentation. In many countries, including Australia, a treatment decision is made on the initial radiographs (degree of displacement) with no trial of closed treatment first. Therefore, the current study reflects that practice by randomising based on the initial films. It is the consideration of many (particularly in Australia and the US) that "stability" is decided on the initial films (displacement, comminution) and "reducibility" decided on the post-reduction films."
3. Adverse events / fracture non-union: The authors list "fracture non-union" as an adverse event, but I found no mention whether they plan to routinely x-ray patients at 6 months (or at a later time point) or whether the need of x-ray is determined by symptoms? If the latter, then one could consider adding "symptomatic fracture non-union" (although asymptomatic non-union has little clinical relevance in the end.)?
We have edited the manuscript to reflect this helpful suggestion. "Adverse events will be defined as:
• Symptomatic fracture non-union (3 of 4 cortices not united radiographically at minimum 6 months)" 4. Cast group: The authors note: "Participants in this group will be treated with a closed reduction and cast immobilisation, avoiding wrist flexion, within two weeks of the initial injury." -Avoiding wrist flexion: Although I fully agree with the authors" decision to aim for a more "neutral position" of the wrist in the cast group, I wonder whether a brief rationale for this would be warranted? In the end, the classic "pronation-flexion-ulnar deviation"-combo was the treatment-of-choice for decades and some might still argue for its merits…?
We have edited the manuscript to reflect this helpful suggestion. "Avoiding wrist flexion" is consistent with standard casting practice in Australia. Immobilisation of a distal radius fracture in flexion has been associated with an increased risk of fracture displacement as well as finger and MCPJ stiffness (Gupta, 1991) . Also, immobilisation in a cast that is too restrictive and excessively flexed has been associated with an increased risk of chronic regional pain syndrome (Sebastin, 2011; Safarfashandi et al, 2013).
5. "…within 2 weeks of the initial injury": Just to be absolutely sure I understand the authors" intentions correctly, you plan to consider someone with a 14-day old wrist fracture (with no prior treatment) to be eligible for randomization? I do realize that there is really no point in setting too stringent of a threshold for this, but I wonder whether the "anticipatable treatment efficacy" of both interventions are equal at this "somewhat late" time point? For the surgery group, this should not make a difference, as the fracture can still be "quite easily" reduced (after some excision of the preliminary callus/scarring at the fracture site), but does the same apply to closed reduction (cast group)? One could obviously say that this is essentially what you plan to study, but my concern is that even so, the "anticipatable prognosis" is not necessarily the same. Having said all this, I do realize that my concern is truly valid for those > 10 days post-injury, who most likely represent a minority of the patient population. Nevertheless, a comment (even in the response letter) seems appropriate. Yes, we agree that there is a lack of clarity around the possibility of achieving closed reduction around 10-14 days post injury. We expect all participants to be seen and recruited within the first one to two days of injury but have allowed up to 14 days to accommodate some treatment delays. We consider the 14-day window to be on the outer limit of "reducible" for closed treatment and therefore would prefer to keep the limit unchanged.
Reviewer: 2 Thank you for the opportunity to review this interesting and very well written protocol paper. It is unclear to this reviewer if the study has already commenced. Thus, all comments are given as has the study not started yet. If recruitment has started please disregard comments that cannot be changed at this time. My most important comments relate to the collection of adverse events, the suggested analysis of data and the implication of the large amount of study sites. Other than that, comments are very minor. Introduction:
The introduction is very well written and argues well for the presence of equipoise justifying this study. Thank you, no response required 1. Page 7, lines 11-12: The word "of" is missing between "most these". Correction made 2. Page 7, line 30: Suggest to remove the word "of" after "In 2011, of…" Correction made
Method and Analysis: 3. Page 9, lines 24-25: Suggest labelling the primary outcome as "patient reported outcome" rather than "questionnaire" as this may cover all sorts of things. Also, I would suggest, if possible, to collect all information electronically to facilitate less loss of data in paper format, given the large amount of study sites. Correction made. We have edited the manuscript according to this helpful suggestion; "The primary outcome (patient reported outcome) will be collected by a blinded assessor." We appreciate the suggestion of allowing direct entry of patient reported outcomes electronically via an email reminder. This has been added to the protocol as; "Data Collection; Primary data collection from site investigators will be paper-based but direct electronic data entry will also be allowed. Participant follow up will be by telephone, but the option of electronic data capture by participants (incorporating electronic reminders) will be available."
4. Page 10, lines 44-47: It is not clear for this reviewer what stratification for "minimisation" cover. What do the authors mean by adjusting the randomization for gender and age? Does this also cover stratification? Adjusting is a term that is usually reserved for the statistical analysis in order to try to take confounding factors into account. We have improved the phrasing of our randomisation approach as follows: "Participants will be randomised using the method of minimisation. Randomisation will be stratified by site, and minimisation, adjusting for gender and age (60-74 years and >74 years), will be employed as recommended by the NHMRC Clinical Trials Centre who will provide the randomisation service. Minimisation (adaptive stratified sampling) aims to reduce imbalance between the groups on prognostic factors which can occur despite random allocation of treatment. Here, age and gender will be included in the minimisation algorithm for randomisation."
5. Page 10-11: I would suggest the authors to stick to the "plate group" and "cast group" labelling and refrain from "intervention" and "control". The authors very nicely outlined that there is almost a 50/50 split in the use of treatments thus I believe simply labelling the groups for what they are would be more correct. Correction made. The suggested changes to "plate group" and "cast group" have been incorporated into the manuscript.
6. Page 11, lines 45-49: I would suggest providing the home exercise program in a supplementary appendix. The exercise part of trials is usually poorly described not allowing for full replication in clinical practice afterwards. The patient handout, including the suggested exercises is included as an appendix.
7. Page 12, secondary outcomes: I would strongly suggest the authors NOT to try and make a predefined exhaustive list of adverse events (complications). Recording of adverse events is a challenge. Preferably ALL adverse events should be recorded disregarding any causal relationship with the treatment/injury. Adverse events tend to be underestimated if such causal relation is trying to be inferred and these are most often based on nothing more than personal opinion. In addition, some form of adjudication panel is usually recommended. Adverse events have included some specific complications, but by using the term "including" we have not restricted the list of adverse events. "Safety Considerations" provides details on how the data safety monitoring board will be comprised and describes functions of the board, including monitoring adverse events; "An independent data safety monitoring board (DSMB) will be established at the commencement of the trial. The board will convene four months after trial commencement to review study progress and, where appropriate, provide advice on issues regarding the scientific aspects of study conduct (eligibility, recruitment rates, compliance) and any emerging evidence as it relates to the trial. The DSMB will reconvene subsequently to review progress if any recommendations were made after the initial review. If not, the DSMB will only meet as required; that is, if any adverse event (defined below) occurs. The DSMB will be required to decide whether the adverse event is related to the trial interventions or not. If there appears to be an atypical trend in adverse events, trial suspension will be considered. The DSMB will comprise three members who are not investigators (an orthopaedic surgeon, a physical therapist, and a statistician /epidemiologist), as well as one investigator."
8. Page 12, sample size: Have the authors considered that with 32 sites, each site will on average only include 5 patients for the trial (and around 15 patients in total including the cohort). Could this have any impact on the data? Often (though similar) some practice variation in the delivery of treatment exists between sites -have the authors considered to deal with this in any way? It is anticipated that recruitment will vary between sites. To account for this, randomisation will be stratified by site. Practice is not expected to vary widely between sites as all surgeons are qualified under the same system.
9. Page 13, data analysis: I have some concerns regarding the statistical analysis. First of all, I do not understand why the primary outcome/analysis is the PRWE score at 12 months. As I understand this score is also collected at baseline (I am not particular familiar with this score). Usually, when trying to assess if one treatment provides better improvement than the other the primary outcome is the between group difference in change from baseline to the primary follow-up point (in this case 12 month). Testing the difference at 12 month does, strictly speaking, not answer the study question in this reviewers opinion. In addition, I would suggest using some form of repeated measures analysis for the primary analysis (i.e. mixed linear random effects model or similar). This type of model will take into account loss to follow-up and use all available data improving point estimates and narrowing confidence intervals. With the present analysis approach (i.e. t-test) only patients with data at 12 months will be used in the analysis. We have changed the baseline measures in that we will no longer collect PRWE at baseline. It will be assumed that all participants had no significant wrist disability at baseline. We agree that change in health status (e.g. pre versus post joint replacement change in KOOS score) measures improvement but this is for conditions where the baseline is abnormal. Baseline PRWE (post fracture) would be abnormal as the participants would not be able to use the arm and would be in severe pain. This would vary depending on exactly when they answered the survey. Asking them to recall their preinjury wrist function is not validated and is confusing for the participants, as we have already seen that some participants have not understood the retrospective nature of the question and have answered as they are at the time (with a fresh fracture). This means that the primary outcome will not be a measure of change but rather a measure of pain and disability at 12 months. This is a reasonable measure in a randomised trial where any pre-injury difference in wrist function is likely to be evenly distributed and where no pre-existing problems with wrist function are expected. We have clarified the description of data analysis in the protocol; "The primary outcome is the PRWE score at 12 months. An analysis of covariance will be used to compare the mean PRWE between the two independent groups. Intention to treat analysis will be performed in the primary analysis. A per-protocol analysis (including participants according to treatment received) will be added as a secondary analysis. Analysis of secondary outcomes will include mixed model analyses, comparing secondary outcomes between timepoints." 10. It is also unclear how missing data will be treated. The authors write that this will be done in accordance with the different outcome tools. However, I guess this only provide a solution for missing ITEMS on the individual outcomes scores? What will the authors do with those patients who are missing completely at one or more follow-ups (lost to follow-up) at the primary end point? I think that the "no missing data imputation" will be a poor option (i.e. implying only those with full data set will be analysed -this is generally not what intention to treat analysis cover). We interpret intention to treat to be the analysis of participants in the groups to which they were randomised, where such analysis is possible. That is, if participants are lost to follow up, they cannot be included in the denominator and therefore the only way their data can be included in the numerator is by imputation, usually based on derivations from known data. In consultation with our statistician, we will impute data missing at the primary end-point if greater than ten percent of data are missing. We have changed the protocol according to this suggestion: "Attempts will be made to minimise missing data, such as obtaining multiple contact details at recruitment and using telephone follow up rather than mail. Missing data will be dealt with according to the instructions on the use of the outcome tools (PRWE, DASH and EQ-5D-5L). If greater than ten percent of data is missing from the randomised sample, then missing data will be imputed." 
VERSION 2 -REVIEW

REVIEWER
